BIFIDOBACTERIUM LACTIS HN019™
Learn more about our premium strain for digestive health
AIM OF THE STUDY
This study was designed to determine the dose response effect of B. lactis HN019™ formulation on the reduction of colonic transit time in healthy adults.
PRODUCT FORMULA
- B.lactis HN019™ low dose (1.88 Billion CFU/day)
- B. lactis HN019™ (17 Billion CFU/day)
STUDY DESIGN
14 day, Triple blind, randomised, placebo controled
SUBJECTS
100 healthy adult patients
PUBLICATION
Scand J Gastroenterol, 25 April 2011

An average reduction of colonic transit time:
- 28 hours at 17 Billion dose (p<0.05)
- 19 hours at 1.8 Billion dose (p<0.05)
For both groups, a significant reduction in the severity of both upper and lower GI symptoms such as:
- Constipation (p<0.01)
- Abdominal pain (p<0.01)
- Irregular bowel movement (p<0.05)
In addition to Waller study, Dietary supplementation with B. Lactis HN019 in combination with other probiotics or prebiotics improved intestinal transit time.
(Magro et al, 2014), (Ibarra et al, 2018), (Waitzburg et al, 2013)


Mean absolute change in GI symptom frequency score over the 14-day supplementation period. Self rated score on a numeric scale anchored at 1 = never and 100 = always. * p<0.05, ** p < 0.01, ***p < 0.001
011)
Mean absolute change in GI symptom frequency score over the 14-day supplementation period. Self rated score on a numeric scale anchored at 1 = never and 100 = always. * p<0.05, ** p < 0.01, ***p < 0.001

*Based on an IQVIA ProVoice® survey of Primary Care Physicians who preferred a probiotic strain for improving overall digestive health after review of select clinical studies; December 2019. This claim cannot be used without a trade mark licensing agreement from IFF or its affiliates.
Good gut health is key to overall health, especially when it comes to digestion. That’s why IFF offers clinically-documented strains and pre-formulated blends to help restore our guts to optimal function and efficiency.
